Immunosuppressive therapy prevents XXXX .

@entity1 @entity500 @entity229 @entity117 @entity2396 @entity262 @entity786 @entity134 @entity230
OBJECTIVES: This study reviews the clinical outcome of a series of @entity1 with @entity2396 before and after immunosuppressive therapy. BACKGROUND: Despite anti-inflammatory treatment, some @entity1 with acute @entity2396 experience repeated relapses of the disease. The use of @entity230 for the treatment of @entity2396 remains controversial. METHODS: Twelve @entity1 (4 @entity1 , 8 @entity1 ; mean [+/- SD] age 35.9 +/- 17.2 years, range 15 to 65) with @entity2396 unrelated to any @entity262 were selected. All 12 @entity1 previously received ineffective short-term courses of low dose @entity230 and had a total of 39 relapses during a mean follow-up period of 14.2 months (range 4 to 50). A 3-month course of treatment with @entity229 , at an immunosuppressive dosage, was started (1 to 1.5 mg/kg body weight per day for 4 weeks, then gradually withdrawn). When @entity229 reduction was undertaken, all @entity1 started a 5-month course of treatment with @entity117 (1.6 g/day until @entity134 suspension, then reduced to 0.8 g/day). RESULTS: During a mean follow-up period of 41.6 months (range 7 to 104), immunosuppressive treatment with high dose @entity229 resulted in stable remission in all except one @entity1 , who experienced one relapse. In this @entity1 , the addition of @entity500 to @entity229 induced a persistent remission, which remained after 1-year follow-up. During treatment, three @entity1 had severe @entity134 -related adverse effects that in two @entity1 required replacement of @entity229 with @entity500 and @entity786 , respectively. This variation in the immunosuppressive regimen did not modify the favorable clinical outcome. CONCLUSIONS: The dose and duration of @entity134 treatment are critical factors in preventing @entity2396 . High dose @entity229 with @entity117 should be considered in the treatment of @entity2396 resistant to anti-inflammatory therapy. @entity786 or @entity500 should be reserved for @entity1 who do not respond to high dose @entity229 or who experience severe complications related to @entity134 therapy.
